Tempest Therapeutics (NASDAQ:TPST – Get Free Report) and Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.
Earnings & Valuation
This table compares Tempest Therapeutics and Karyopharm Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tempest Therapeutics | N/A | N/A | -$26.26 million | ($6.01) | -0.21 |
| Karyopharm Therapeutics | $146.07 million | 1.47 | -$196.04 million | ($15.09) | -0.63 |
Risk and Volatility
Tempest Therapeutics has a beta of -1.85, meaning that its share price is 285% less volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and target prices for Tempest Therapeutics and Karyopharm Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tempest Therapeutics | 1 | 1 | 0 | 0 | 1.50 |
| Karyopharm Therapeutics | 1 | 0 | 5 | 1 | 2.86 |
Karyopharm Therapeutics has a consensus target price of $17.17, suggesting a potential upside of 80.70%. Given Karyopharm Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Tempest Therapeutics.
Profitability
This table compares Tempest Therapeutics and Karyopharm Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tempest Therapeutics | N/A | -355.61% | -121.21% |
| Karyopharm Therapeutics | -129.02% | N/A | -120.29% |
Insider & Institutional Ownership
22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 6.3% of Tempest Therapeutics shares are owned by insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Karyopharm Therapeutics beats Tempest Therapeutics on 9 of the 14 factors compared between the two stocks.
About Tempest Therapeutics
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
